Cameron Mitchell was previously the CEO and co-founder of Synchrony Pharma. The sale of Synchrony Pharma to CNX in July 2022 excluded its product development pipeline. In the role of CEO for Galvany Pharma, he will be responsible to commercialise both its’ current and future product pipeline. Previously he was a member of the European management team at Cephalon, during a period of rapid expansion (now part of Teva ). Prior to joining Cephalon, he was part of the management team that grew Zeneus Pharma Limited into a successful specialty pharmaceutical company, and, subsequently managed the integration with Cephalon. Prior to this, he held senior positions at Elan Pharmaceuticals, Accenture, and, GlaxoSmithKline. He holds a BSc Pharmacy from Strathclyde University, is a Responsible Pharmacist, and, is a member of the Royal Pharmaceutical Society of Great Britain.

Graham was an integral member of the Synchrony Pharma management team from inception as a co-founder through to its subsequent sale. Graham Smith is responsible for managing Galvany’s Supply Chain, QA, and Technical/Scientific functions. He has extensive experience in managing Pharmaceutical Operations having previously held senior positions at Zeneus Pharma, Cephalon and GE Healthcare. Graham has a degree in Chemistry and Management from King’s College London and is a member of the Royal Society of Chemistry.